Reuters
Skincare company Galderma was on course to raise 2.3 billion ($2.6 billion) Swiss francs from its upcoming initial public (IPO) offering after a positive response from potential investors. The company, whose products includes Cetaphil, a product for damaged and sensitive skin, as well as fillers and skin creams, early on Wednesday announced a price range of 49 to 53 Swiss francs for its flotation - likely to be one of the biggest in Europe this year. The offering consists of up to 40.5 million new shares and 277,000 existing shares, the company said.
